Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| GLOBAL GEOPH | GGS | 7.79% |
| STAAR SURGIC | STAA | 6.23% |
| KAPSTONE PAP | KS | 6.14% |
| HORNBECK OFF | HOS | 5.99% |
| ANIKA THERAP | ANIK | 5.55% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Strengthening its position in the energy space, the operator of regulated future exchanges – CME Group Inc. (CME - Analyst Report) announced a comprehensive set of new natural gas and power markets. All the products from this suite will be listed on the New York Mercantile Exchange (NYMEX).
Accordingly, CME Group will now offer 164 natural gas contracts and 48 power contracts for the four most liquid North American ISOs within its new natural gas and power portfolio. Moreover, the contracts will be accessible at 52 trading hubs and will be listed as futures on CME Globex, NYMEX and CME ClearPort.
Additionally, these energy futures contracts will also be available at CME Direct – a new technology that aids parallel trading of exchange-listed and over-the-counter (OTC) markets. Launched in May 2012, CME Direct already offers a basket of standard energy products including Henry Hub Natural Gas.
The launch of new energy futures and expansion of the portfolio is another attempt by CME Group to evolve through its hedging strategies, product modification and innovation, thereby supporting volumes and the top-line growth in the long run. Additionally, such products enhance transparency and risk-management features to the trading, which should help in gaining the confidence and attracting the untapped customer-base.
The business development also appears crucial given that arch-rival IntercontinentalExchange Inc. (ICE - Analyst Report) offers more than 730 cleared OTC energy contracts, including more than 640 new cleared OTC contracts since the launch of ICE Clear Europe in November 2008. Hence, over the past several quarters, the futures exchanges have launched multiple new coal, natural gas, gas oil and crude oil futures contracts, in order to extensively penetrate the rapidly expanding energy sphere. We believe that the latest offering will further enhance CME Group’s market retention capacity, also reflecting sound utilization of its capital.
CME Raises $750 million Via Notes
Last week, CME Group announced the sale of unsecured senior notes worth $750 million. The proceeds of these notes are expected to be utilized to enhance its business operations and redeem its 5.4% notes that are slated to mature in August 2013.
Accordingly, the $750 million ten-year fixed-rate notes are issued at a price of $99.691, bearing a coupon rate of 3.00% and yield rate of 3.036%. These notes are slated to mature on September 15, 2022. These callable notes are projected to have a spread of 145 basis points (bps) over the US Treasuries. Interest on the notes will be paid semi-annually, in equal instalments.
Meanwhile, CME Group appointed Barclays Capital Plc (BCS - Snapshot Report), UBS AG (UBS) and Merrill Lynch, Pierce, Fenner & Smith Inc. of Bank of America Corp. (BAC - Analyst Report) as the underwriters. Alongside, Citigroup Inc. (C - Analyst Report), Mitsubishi UFJ Financial Group Inc. (MTU - Analyst Report) , Wells Fargo & Co. (WFC - Analyst Report), BMO Capital Markets Corp. and Lloyds Securities Inc. are the joint book-running managers for the sale.
The above-mentioned set of fixed-rate notes carry a rating of “Aa3” and “AA-” from Moody’s Investor Service ofMoody’s Corp. (MCO) and Standards & Poor’s (S&P), respectively.
The increased activity on the business development front elucidates the requirement for increased capital, whereas the company’s liquidity is well-cushioned with higher cash and cash flow position in the first half of 2012. The latest long-term notes mitigate any cautious outlook in the near term, although higher interest expenses will continue to weigh on the financials.
Conversely, CME Group is considerably exposed to interest rate volatility and rising competition, which again demand for strong capital requirements to better manage any fluctuations. Yet, we believe that a gradual economic recovery and stable debt ratings are expected to drive volumes further. Moreover, the company’s efforts to promote, expand and cross-sell its core exchange-traded business through meaningful acquisitions, a strong portfolio along with its global presence will generate a decent upside in the long run.
CME Group carries a Zacks Rank #3 that implies a short-term Hold rating, while the long-term recommendation stands at Neutral.
Get the full Analyst Report on ICE - FREE
Get the full Analyst Report on CME - FREE
Get the full Snapshot Report on BCS - FREE
Get the full Analyst Report on WFC - FREE
Get the full Analyst Report on C - FREE
Get the full Analyst Report on BAC - FREE
Get the full Analyst Report on MTU - FREE